Angiotech's corporate partner, Boston Scientific, announces completion of clinical trial enrollment for third-generation drug-eluting stent



    
    PERSEUS clinical program to evaluate TAXUS(R) Element(TM) Platinum
    Chromium Stent
    

    VANCOUVER, Oct. 8 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:   ANPI,
TSX: ANP), a global specialty pharmaceutical and medical device company, today
reported that its corporate partner, Boston Scientific Corporation (NYSE:  
BSX), has completed enrollment in the PERSEUS trial, designed to evaluate the
third-generation TAXUS(R) Element(TM) paclitaxel-eluting coronary stent. The
Element Stent platform features the proprietary Platinum Chromium Alloy, and
is designed to enable thinner struts for increased flexibility, a lower
profile and improved radial strength, recoil and radiopacity.
    "The new alloy and stent design of TAXUS Element provides improved
deliverability and visibility, even in patients with complex and challenging
anatomy," said Dean J. Kereiakes, M.D., Medical Director at the Christ
Hospital Heart and Vascular Center and the Lindner Research Center in
Cincinnati, the principal investigator for the trials. "I am very enthusiastic
about the potential the TAXUS Element Stent offers me to treat a broader range
of patients."
    Currently the leading drug-eluting stents worldwide, TAXUS Stent Systems
have been evaluated by the industry's most extensive randomized, controlled
clinical trial program, as well as studied in more than 35,000 real-world
patients enrolled in post-approval registries. The PERSEUS clinical program
has enrolled nearly 1,500 patients at 100 U.S. and international centers since
July 2007, and will compare the TAXUS Element Stent to the prior-generation
TAXUS(R) Express(2)(TM) Stent marketed in the United States since 2004.
    "We congratulate our partner, Boston Scientific, on completing enrollment
in this historic and innovative study," said Dr. William Hunter, President and
CEO of Angiotech. "This is an important milestone and represents another step
towards expanding our paclitaxel franchise into next-generation stent systems
and strengthening our world-class portfolio of drug-coated devices."
    The TAXUS Element Stent is an investigational device and is limited by
Federal law to investigational use only and is not available for sale. Boston
Scientific currently anticipates achieving CE Mark approval for the European
markets in 2009.

    
    Cautionary Statement Regarding Forward-Looking Statements
    ---------------------------------------------------------
    

    Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the words
"believes," "may," "plans," "will," "estimate," "continue," "anticipates,"
"intends," "expects" and similar expressions, constitute "forward-looking
statements" within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and "forward-looking information" within the meaning of
applicable Canadian securities laws. All such statements are made pursuant to
the "safe harbor" provisions of applicable securities legislation.
Forward-looking statements may involve, but are not limited to, comments with
respect to our objectives and priorities for the second half of 2008 and
beyond, our strategies or future actions, our targets, expectations for our
financial condition and the results of, or outlook for, our operations,
research development and product and drug development. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors
that may cause the actual results, events or developments to be materially
different from any future results, events or developments expressed or implied
by such forward-looking statements. Many such risks, uncertainties and other
factors are taken into account as part of our assumptions underlying these
forward-looking statements and include, among others, the following: general
economic and business conditions, both nationally and in the regions in which
we operate; market demand; technological changes that could impact our
existing products or our ability to develop and commercialize future products;
competition; existing governmental regulations and changes in, or the failure
to comply with, governmental regulations; adverse results or unexpected delays
in pre-clinical and clinical product development processes; adverse findings
related to the safety and/or efficacy of our products or products sold by our
partners; decisions, and the timing of decisions, made by health regulatory
agencies regarding approval of our technology and products; and the
requirement for substantial funding to conduct research and development and to
expand manufacturing and commercialization activities or consummate
acquisitions. In addition, our business is subject to certain operating risks
that may cause any results expressed or implied by the forward-looking
statements in this press release to differ materially from our actual results.
These operating risks include: our ability to attract and retain qualified
personnel; our ability to successfully complete pre-clinical and clinical
development of our products; changes in business strategy or development
plans; our failure to obtain patent protection for discoveries; loss of patent
protection resulting from third party challenges to our patents;
commercialization limitations imposed by patents owned or controlled by third
parties; our ability to obtain rights to technology from licensors; liability
for patent claims and other claims asserted against us; our ability to obtain
and enforce timely patent and other intellectual property protection for our
technology and products; the ability to enter into, and to maintain, corporate
alliances relating to the development and commercialization of our technology
and products; market acceptance of our technology and products; our ability to
successfully manufacture, market and sell our products; the continued
availability of capital to finance our activities; and any other factors
referenced in our other filings with the Securities and Exchange Commission
(the "SEC"). Given these uncertainties, assumptions and risk factors, readers
are cautioned not to place undue reliance on such forward-looking statements.
Except as required by law, we disclaim any obligation to update any such
factors or to publicly announce the result of any revisions to any of the
forward-looking statements contained in this press release to reflect future
results, events or developments.
    Boston Scientific Corporation acquired worldwide exclusive rights from
Angiotech to use paclitaxel on its coronary stent products and has
co-exclusive rights to certain peripheral vascular and non-vascular products.

    TAXUS(R) Element(TM) and Express(2)(TM) are trademarks of Boston
Scientific Corporation.

    About Angiotech

    Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and
medical device company with over 1,500 dedicated employees. Angiotech
discovers, develops and markets innovative treatment solutions for diseases or
complications associated with medical device implants, surgical interventions
and acute injury. To find out more about Angiotech (NASDAQ:   ANPI, TSX: ANP),
please visit our website at www.angiotech.com.





For further information:

For further information: DeDe Sheel, Investor Relations and Corporate
Communications, Angiotech Pharmaceuticals, Inc., (415) 293-4412,
dede.sheel@fdashtonpartners.com

Organization Profile

Angiotech Pharmaceuticals, Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890